UroGen Pharma Ltd (URGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.28B
Last updated: Nov 17, 2026 at 11:05 AM ET
UroGen Pharma Ltd (URGN) Competitors
The companies most similar to UroGen Pharma are Ultragenyx (RARE), Precigen (PGEN) and Uniqure NV (QURE). By market cap, UroGen Pharma ranks 8th of the 13 companies on this page; Aurinia Pharmaceuticals (AUPH) is the largest at $2.11B. The median P/E of the 4 companies with a P/E is 27.3x.
Peer Comparison
URGN's ROIC of -73.7% is below the peer median of -13.0%, and its revenue growth of 223.9% is above the median of 24.1%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| UroGen Pharma (URGN) | $1.28B | N/A | 5.7x | -26.3% | -73.7% | 223.9% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Precigen Inc (PGEN) | $1.63B | 98.6x | 9.9x | 15.5% | 18.9% | 2438.0% | 0.00% |
| Uniqure NV (QURE) | $1.67B | N/A | 75.8x | 0.0% | -57.9% | 40.4% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Aurinia Pharmaceuticals Inc (AUPH) | $2.11B | 15.2x | 6.4x | 97.7% | N/A | 13.9% | 0.00% |
| Geron Corporation (GERN) | $622.98M | N/A | 2.9x | -22.0% | -7.4% | 27.4% | 0.00% |
| Tourmaline Bio Inc. (TRML) | $1.23B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pharming Group NV (PHAR) | $891.80M | 39.3x | 2.4x | 6.3% | 7.9% | 20.8% | 0.00% |
| Septerna, Inc. Common Stock (SEPN) | $2.03B | N/A | 20.3x | -61.3% | N/A | -12.2% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Prime Medicine, Inc. Common Stock (PRME) | $949.85M | N/A | 105.5x | 0.0% | N/A | 243.9% | 0.00% |
| Peer median | $1.52B | 27.3x | 6.6x | 0.0% | -13.0% | 24.1% | 0.00% |
Similar Companies
These are the 12 companies most similar to UroGen Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Precigen Inc (PGEN) | Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland. | PGEN competitors |
| Uniqure NV (QURE) | uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. | QURE competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Aurinia Pharmaceuticals Inc (AUPH) | Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. | AUPH competitors |
| Geron Corporation (GERN) | Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic... | GERN competitors |
| Tourmaline Bio Inc. (TRML) | Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions... | |
| Pharming Group NV (PHAR) | Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States... | PHAR competitors |
| Septerna, Inc. Common Stock (SEPN) | Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform. | SEPN competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Prime Medicine, Inc. Common Stock (PRME) | Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology... | PRME competitors |
Frequently Asked Questions About URGN
Who are UroGen Pharma's main competitors?
The companies most similar to UroGen Pharma include Ultragenyx (RARE), Precigen (PGEN), Uniqure NV (QURE), Nuvation Bio (NUVB) and Nurix Therapeutics (NRIX), listed from the closest match.
Who is UroGen Pharma's biggest competitor?
Aurinia Pharmaceuticals (AUPH) is the largest of the similar companies at $2.11B; Ultragenyx (RARE) is the closest match by business profile, size, sector and industry.
How does URGN stock compare with its competitors?
URGN's P/S is 5.7x against a peer median of 6.6x; its net margin is -26.3% against a peer median of 0.0%.
Which of UroGen Pharma's competitors pays a higher dividend?
UroGen Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is UroGen Pharma bigger than its competitors?
No. UroGen Pharma is 8th by market cap among the 13 companies on this page; the largest is Aurinia Pharmaceuticals (AUPH) at $2.11B.
URGN pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts